CLAIMS

1. Use of a compound represented by Structural Formula VI:



(VI)

or a pharmaceutically acceptable salt thereof, wherein:

X is N

R_B is methyl, ethyl, hydroxy methyl, methoxymethyl, or trifluoromethyl;

R_C is selected from the group consisting of -F, -Cl, -Br, -OH, and -O-(C_1-C_4)alkyl;

m is 2 and each R_A is methyl;

L is –CO-N(R_9R_{10}), wherein R_9 is -(C_0-C_6)alkylene-heterocycloalkyl, -(C_0-C_6) alkylene-aryl, or -(C_0-C_6)alkylene-heteroaryl and each -heterocycloalkyl, -aryl, and -heteroaryl is optionally and independently substituted with 1 to 4 (C_1-C_4)alkyl, and R_{10} is H or -(C_1-C_6)alkyl; or

L is –COO–R'$_9$, wherein R'$_9$ is independently selected from the group consisting of -(C_1-C_6)alkyl, -(C_0-C_6)alkylene-heterocycloalkyl, -(C_0-C_6)alkylene-aryl, and -(C_0-C_6)alkylene-heteroaryl and each -(C_1-C_6)alkyl, -heterocycloalkyl, -aryl, and -heteroaryl is optionally substituted with 1 to 4 substituents independently selected from the group consisting of -F, -Cl, -Br, and -(C_1-C_6)alkyl;

for the preparation of a medicament for the treatment of hyperinsulinaemia in a subject suffering from a condition selected from insulinoma, congential hyperinsulism, polycystic ovary syndrome, Beckwith-Wiedemann syndrome and post-gastric bypass surgery.

2. The use of Claim 1, wherein the condition is an insulinoma.

3. The use of any one of Claims 1 or 2, wherein L is –COO–R_9, and R_9 is selected from the group consisting of: methyl, ethyl, propyl, i-propyl, butyl, sec-butyl, t-butyl, and trifluoromethyl.

4. Use of a compound represented by the following structural formula:



or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of hyperinsulinaemia in a subject suffering from a condition selected from insulinoma, congential hyperinsulism, polycystic ovary syndrome, Beckwith-Wiedemann syndrome and post-gastric bypass surgery.

5. The use of Claim 4, wherein the condition is an insulinoma.

6. The use of any one of Claims 4 or 5, wherein the compound is represented by the following structural formula:



or a pharmaceutically acceptable salt thereof.

7. Use of a compound represented by the following structural formulas:

,

,

,

, or

,

or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of hyperinsulinaemia in a subject suffering from a condition selected from insulinoma, congential hyperinsulism, polycystic ovary syndrome, Beckwith-Wiedemann syndrome and post-gastric bypass surgery.

8. The use of Claim 7, wherein the condition is an insulinoma.

9. Use of a compound represented by the following structural formulas:


,


,


,


, or


,

or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of hyperinsulinaemia in a subject suffering from a condition selected from insulinoma, congential hyperinsulism, polycystic ovary syndrome, Beckwith-Wiedemann syndrome and post-gastric bypass surgery.

10. The use of Claim 9, wherein the condition is an insulinoma.

11. Use of a compound represented by the following structural formulas:



or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of hyperinsulinaemia in a subject suffering from a condition selected from insulinoma, congential hyperinsulism, polycystic ovary syndrome, Beckwith-Wiedemann syndrome and post-gastric bypass surgery.

12. The use of Claim 11, wherein the condition is an insulinoma.

13. Use of a compound represented by the following structural formulas:



or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of hyperinsulinaemia in a subject suffering from a condition selected from insulinoma, congential hyperinsulism, polycystic ovary syndrome, Beckwith-Wiedemann syndrome and post-gastric bypass surgery.

14. The use of Claim 13, wherein the condition is an insulinoma.

15. The use of any one of claims 1-14 wherein the subject is a mammal.

16. The use of Claim 15, wherein the subject is a human.